Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Koonal Shah;Mike Herdman;Yvonne Summers;Nancy Devlin;Patricia Cubi-Molla

Contract Research from Office of Health Economics

Abstract: Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response. In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age/sex-matched population samples. This study was funded by Roche Products Ltd. Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response. In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age/sex-matched population samples. This study was funded by Roche Products Ltd.

Keywords: Quality; of; Life; in; Long-term; Cancer; Survivors:; Implications; for; Future; Health; Technology; Assessments; in; Oncology (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2018-06-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/quality-life-long ... rm-cancer-survivors/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002023

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).